Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035422 | 0.77 | KDM4E (0.38) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL2871668 | 0.74 | CNR1 (0.44) | KMT2AKDM4EMAPT | |
| SCHEMBL16945271 | 0.74 | MAPT (0.43) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL16447554 | 0.72 | RAB9A (0.45) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL23214476 | 0.69 | NPSR1 (0.36) | KMT2AKDM4EALDH1A1MAPK8MAPK9 | |
| SCHEMBL33526512 | 0.69 | DAPK3 (0.35) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL31211383 | 0.68 | RXFP1 (0.42) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL19697709 | 0.67 | ALDH1A1 (0.45) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL17810292 | 0.67 | SMN1; SMN2 (0.39) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL15812307 | 0.67 | GUCY1B2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772249-B2 | Imidazo[1,2-b]pyridazine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | KMT2A 3162/4885KDM4E 3054/4885ALDH1A1 4011/4885 |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | KMT2A 3162/4885KDM4E 3054/4885ALDH1A1 4011/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | KMT2A 2608/4885KDM4E 3096/4885ALDH1A1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.